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The Scope

A wonder drug
against cancer,
HIV and other
diseases?
Researchers at the Massey Cancer Center have
found that AR-12 can neutralize the proteins
that protect cancer cells. The drug also may
be effective against Ebola, Zika and bacterial
infections.
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haperones make sure students stick together
during class field trips. The cells in your body
have chaperones, too: “chaperone” proteins that
keep a cell’s shape intact. Usually, that’s good.
But when someone has cancer, these proteins
allow cancer cells to reproduce and spread
throughout the body.
So a VCU researcher has found a way to ditch
those annoying chaperone proteins – and stop
the spread of cancer – just like students might
ditch their chaperones on a field trip.
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‘We saw interesting
effects with the AR12 drug against those
viruses and against
bacteria,’ Dent says.
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Dr. Paul Dent, a researcher at VCU’s Massey
Cancer Center, is experimenting with a new drug
that targets the chaperone proteins that protect
cancer cells.
The drug, called AR-12, overrides the
chaperones from holding a cell’s shape. AR-12
does its damage by breaking apart the host cell,
which is needed for cancer cells to reproduce
(otherwise they’ll die). This secret weapon has
the potential to fight off not only cancer but also
Ebola, Zika and the human immunodeficiency
virus, as well as bacterial infections.
“We saw interesting effects with the AR-12 drug
against those viruses and against bacteria,” Dent
said.
He said cancer cells are very active, thus
creating more enzymes. Once the cancer
attaches to a cell, chaperone proteins stick with
the enzyme and keep it together. But AR-12 can
render the chaperones useless.

Dr. Paul Dent, center, and his team of researchers at the Massey
Cancer Center. (Photo courtesy of Dr. Dent)

“These proteins are flopping around like a
jellyfish out of water when they’re catalyzing,
which means they can fall out of shape easily,”
Dent said. “And if they fall out of shape, they’re
dead.”
The chaperones protect the cancer by giving it
a safe place to live. “The chaperone is snuggled
up to the enzyme,” Dent said. “And if the enzyme
should ever get a bit incorrectly shaped, the
chaperone spends some ATP (adenosine
triphosphate) energy and keeps it together.”
You can’t destroy the cancer while the
chaperones are protecting it. And neutralizing
the chaperones is tricky because there is more
than one kind.
One family of chaperone proteins is called
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HSP90; another is HSP70. Dent said that when
HSP90 is attacked, HSP70 is formed – and vice
versa. This has posed issues for researchers
because when they target one chaperone family,
a different one replaces it and protects the cell.
Previous chaperone inhibitors could target only
HSP90 or HSP70. This where the drug AR-12
is useful: It blocks both the HSP90 and HSP70
families.
“Unlike many drugs that target one specifically,
this drug targets both, albeit not as potently,”
Dent said. When AR-12 prevents the chaperones
from holding a cell together, the cell loses its
shape and kills the cancer.
But this possible wonder drug is not on the
market yet. Research has been done on AR12 for years now, but the drug’s owner, Arno
Therapeutics, is still seeking approval from the
U.S. Food and Drug Administration.
“AR-12 was tested in cancer patients. Although
it was safe and showed some activity, the drug
uptake in patients was variable,” Dent said. “So
the FDA told Arno Therapeutics they needed to
reformulate AR-12 before doing more clinical
work.”
Dent said he is disappointed that the company
hasn’t reformulated the drug so that testing can
resume.
On its website, Arno Therapeutics describes
itself as “a biopharmaceutical company that
focuses on the clinical development of targeted
cancer therapies and novel drug candidates for
unmet medical needs.” •

